Mutant MHC class II epitopes drive therapeutic immune responses to cancer

Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nature
Main Authors: Kreiter, Sebastian, Vormehr, Mathias, van de Roemer, Niels, Diken, Mustafa, Löwer, Martin, Diekmann, Jan, Boegel, Sebastian, Schrörs, Barbara, Vascotto, Fulvia, Castle, John C., Tadmor, Arbel D., Schoenberger, Stephen P., Huber, Christoph, Türeci, Özlem, Sahin, Ugur
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4838069/
https://ncbi.nlm.nih.gov/pubmed/25901682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature14426
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados